Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study

References

• Smolen JS, Aletaha D. Monitoring rheumatoid arthritis. Curr Opin Rheumatol. 2011; 23:252–258.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Singh G, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007; 17:283–289.
   PubMedGoogle Scholar
• Jayakumar K, Norton S, Dixey J, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford). 2012; 51:169–175.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 2012; 24:319–326.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005; 52:2625–2636.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Mannalithara A, Inoue E, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008; 67:1153–1158.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69:631–637.
   PubMed Web of Science ®Google Scholar
• Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. 2011; 63:2865–2872.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Seto Y, Tanaka E, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol. 2012. doi:10.1007/s10165-012-0702-1.
   Google Scholar
• Iikuni N, Inoue E, Tanaka E, et al. Low disease activity state with corticosteroid may not represent ‘true’ low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008; 47:519–521.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Mannalithara A, Inoue E, et al. Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity. Rheumatol Int. 2010; 32:749–757.
   PubMedGoogle Scholar
• Matsuda Y, Singh G, Yamanaka H, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003; 49:784–788.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Tanaka E, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007; 17:98–105.
   PubMedGoogle Scholar
• Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44–48.
   PubMed Web of Science ®Google Scholar
• Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997; 36:551–559.
   PubMedGoogle Scholar
• Emery P, Genovese MC, Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009; 36:1429–1441.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2011; 22:327–338.
   PubMedGoogle Scholar
• Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011; 38:1585–1592.
   PubMed Web of Science ®Google Scholar
• Furst DE. Observational cohort studies and well controlled clinical trials—we need them both!. J Rheumatol. 2004; 31:1476–1477.
   PubMedGoogle Scholar
• Ozminkowski RJ, Burton WN, Goetzel RZ, et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med. 2006; 48:135–148.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Grisar JC, et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010; 69:1058–1064.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011; 63:3702–3711.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Alasti F, Smolen JS. Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. Ann Rheum Dis. 2011; 70:1975–1980.
   PubMed Web of Science ®Google Scholar